Articles tagged with Prostate Cancer
A Swedish study found that PSA screening nearly halves prostate cancer mortality after 14 years. However, the screening was associated with a risk of impotence and urinary incontinence, albeit at lower rates than expected.
A national survey found that 76% of people would take a predictive test to learn about their future health risks, with willingness to pay varying by disease type and accuracy. Respondents were more likely to pay for tests related to breast and prostate cancer, and were willing to alter lifestyle choices after receiving positive results.
A new study found that physical activity is associated with a lower risk of overall mortality and prostate cancer-specific mortality in men with prostate cancer. Men who did more vigorous activity had the lowest risk of dying from the disease.
A new UCSF study reveals that older men with high-risk prostate cancer are frequently under-treated, leading to higher mortality rates. The researchers argue that age should not be a barrier to more aggressive treatments that could lead to potential cures.
A new study published in Retrovirology reveals that cell samples used in previous research were contaminated with XMRV, not the cause of chronic fatigue syndrome. The researchers developed improved methods to detect XMRV and rule out infection by this virus as a cause of the disease.
Researchers found that a slight rise in PSA levels among men taking dutasteride was a stronger indicator of prostate cancer than rising PSA levels in men on a placebo. The study suggests that the drug enhances the ability to detect high-grade cancers, making the PSA test more effective for early diagnosis and treatment.
Scientists from deCODE genetics and academic colleagues report discovering genetic markers that impact individual baseline levels of prostate-specific antigen (PSA). Analyzing four SNPs in tandem with genetic risk factors detected by the deCODE ProstateCancer test yields substantial improvement in PSA screening efficacy.
Researchers identified pomegranate juice components that inhibit the movement of cancer cells and weaken their attraction to a chemical signal. The effects of these components on prostate cancer progression are still controversial and require further testing.
A study found that decreased physician reimbursement for hormone therapy reduced its use in low-risk prostate cancer cases by 40%. However, AST usage remained unchanged in patients with metastatic disease. The decrease is attributed to the real effect of reimbursement change.
A new technology uses metabolic imaging to rapidly assess prostate tumor presence and aggressiveness in real-time. The initial results validate preclinical research linking tumor metabolism speed to growth aggressiveness.
Researchers have identified genetic mutations associated with elevated PSA levels in men diagnosed with prostate cancer, offering potential new biomarkers for disease monitoring. The study's findings suggest that sequencing of selected mitochondrial regions could provide valuable information for prognosis.
Researchers at UCLA found that the protein Bmi-1 plays a crucial role in regulating self-renewal of normal prostate stem cells and transforming healthy cells into prostate cancer cells. Inhibiting Bmi-1 slowed the growth of aggressive prostate cancer in animal models.
Men with longer index fingers are at a lower risk of developing prostate cancer, while those with shorter index fingers are more likely to be diagnosed. The study found that men aged under 60 were 87% less likely to have prostate cancer if their index finger was longer than their ring finger.
Active surveillance outperforms initial treatment for low-risk prostate cancer, providing a higher quality-adjusted life expectancy (QALE) and reducing adverse effects of treatment. The optimal strategy depends on individual patient preferences for surveillance or treatment.
A recent study published in Cancer found that clinical stage does not predict recurrence risk for patients with localized prostate cancer after having their prostate removed. Despite frequent errors in assigning stage, there was no association between clinical stage and prostate cancer recurrence.
A multidisciplinary clinic approach to treating aggressive prostate cancer has been shown to improve survival rates and reduce distress among patients. The study, conducted over 15 years at the Kimmel Cancer Center, found that a team of specialists working together can provide more effective treatment options and better patient outcomes.
A new anti-cancer drug, inecalcitol, has shown encouraging responses in men with hormone-resistant prostate cancer. In a phase II(a) clinical trial, 83% of patients responded to the treatment with a drop in PSA levels of 30% or more within three months.
A new study found a 30-40% higher risk of colorectal cancer among men treated with hormone-based therapy for prostate cancer. The study suggests continued routine preventive care, including colorectal cancer screening, is essential during prostate cancer treatment.
A study published in JNCI Journal of the National Cancer Institute found that men taking androgen deprivation therapy for prostate cancer have a 30-40% increased risk of colorectal cancer. The longer treatment duration, the greater the risk.
A study of over 46,500 prostate cancer patients found that long-term androgen deprivation therapy increases the risk of fractures, especially among older men with pre-existing conditions. The therapy was associated with a 20% increase in first fracture risk and a 57% increased risk of second fractures.
Researchers at Northwestern University have found that a soy-based drug can prevent the movement of prostate cancer cells from the prostate to the rest of the body. The experimental treatment, genistein, has shown beneficial effects on human subjects with localized prostate cancer in a recent phase II study.
Researchers found that the protein N-cadherin is upregulated in prostate cancer that does not respond to hormone therapy, making it a potential target for therapy. The study suggests that a monoclonal antibody targeting N-cadherin may be effective in treating this aggressive form of prostate cancer.
Weill Cornell Medical College researchers discovered secondary mutations in prostate cancer cells that make them lethal. This finding could lead to better tests and individualized therapy for deadly prostate cancers.
Researchers at Johns Hopkins Medicine have developed a technique to culture normal and cancerous prostate tissue for up to a week, enabling accurate predictions of how living tissues respond to therapy. This breakthrough could lead to the creation of individualized medicines for prostate cancer patients.
A recent study found a decline in unnecessary care for prostate cancer patients not likely to benefit from treatment after Medicare policy changes reduced reimbursement. In contrast, patients with clear benefits from the therapy continued to receive it at the same rate.
A new study from the University of Pennsylvania School of Medicine found that intensity modulated radiation therapy (IMRT) minimizes gastrointestinal complications in prostate cancer patients. The study compared IMRT to three-dimensional conformal radiotherapy and found that men treated with IMRT had fewer serious bowel complications.
A study found that intensity modulated radiation therapy (IMRT) minimizes side effects of prostate cancer treatment, particularly gastrointestinal complications. In contrast, urinary side effects did not differ significantly between the two treatments.
Routine prostate cancer screening significantly reduces the risk of metastatic disease within 10 years after treatment. Men diagnosed post-screening had a lower risk of spreading cancer compared to those treated prior to widespread screening.
A large study found that men with localized prostate cancer who take aspirin with radiation therapy or surgery have a lower risk of dying from the disease. The use of anticoagulants reduced the risk of death by 6 percentage points, from 10% to 4%, at 10 years.
The study found that combining hormone therapy and radiation significantly decreased the risk of death among high-risk prostate cancer patients. The addition of radiation did not increase long-term side effects.
Studies show that adding radiation to hormone therapy for prostate cancer increases survival chances, while aspirin use reduces risk of cancer death. Prostate cancer screening improves quality of life by catching the disease earlier, and radiation before surgery keeps colorectal cancer from returning.
A new study by University at Buffalo gastroenterologists reveals that men with prostate cancer are more likely to have precancerous colon polyps, including abnormal adenomas and advanced adenomas. The research suggests these patients should prioritize routine colonoscopies to prevent colorectal cancer.
Researchers at Queensland University of Technology have identified a specific vitamin E constituent that can inhibit the growth of prostate tumors. The treatment, tocotrienol (T3), has shown promise in animal trials, with complete inhibition of tumor formation in over 70% of mice implanted with prostate cancer cells.
A recent study published in European Urology found that nearly 87% of prostate cancer patients who underwent robot-assisted radical prostatectomy had no recurrence after five years. The study, led by Dr. Mani Menon, suggests that robotic-assisted surgery is an effective treatment for localized prostate cancer.
Recent studies published in The Journal of Infectious Diseases found evidence supporting a possible link between XMRV and prostate cancer. However, conflicting reports suggest that XMRV is unlikely associated with chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.
The Phase III trial confirms that abiraterone acetate extends life by four months for patients with advanced prostate cancer, improving median overall survival to 14.8 months. This breakthrough treatment challenges the standard care for men with advanced disease.
A Rutgers-led research team has received a $3.3 million NIH grant to develop technology that combines advanced ultrasound and magnetic resonance images to pinpoint cancerous tissue during biopsies. This could lead to more accurate diagnoses and reduced false negatives.
Researchers discovered that genetic variations impairing phosphodiesterase 11A (PDE11A) enzyme activity increase prostate cancer risk, affecting nearly four times more men than those without the variation. The study suggests PDE11A may have a role in genetic screening for predisposition to prostate cancer.
A phase 3 trial shows cabazitaxel improves overall and progression-free survival in men with advanced multi-drug resistant prostate cancer. The medication was found to be effective in patients whose disease progressed after standard chemotherapy with docetaxel.
A recent study by Mayo Clinic found that radical prostatectomy significantly improves survival rates for men with localized prostate cancer. The procedure has led to excellent overall survival rates, with only 3% of patients dying from prostate cancer.
Researchers have developed a biomarker panel that distinguishes prostate cancer from benign prostate disease and healthy tissue with high accuracy. The panel uses autoantibodies to identify proteins on the surface of cancer cells, enabling early diagnosis and potentially increasing cure rates.
Researchers found that surgery provides high survival rates of 92% for patients with aggressive prostate cancer, outperforming radiation therapy alone in terms of cancer-specific and overall survival. The study suggests that limiting hormone therapy may avoid adverse health consequences for these patients.
Researchers at St. Michael's Hospital discovered that the cholesterol-lowering drug Crestor suppressed human prostate cancer cells grown in mice. This pre-clinical evidence suggests statins could be an effective treatment for prostate cancer, potentially offering a safer alternative to existing therapies.
A study of 43,987 men aged 55-74 found that those with low PSA levels did not have a significant reduction in prostate cancer deaths. Men with high PSA levels benefited more from screening and treatment. The results suggest that aggressive follow-up testing and treatment may not be beneficial for men with low PSA values.
A new analysis found that prostate cancer treatment choices significantly impact long-term care costs. Watchful waiting had the lowest initial and five-year total costs, while hormonal therapy plus radiation and surgery were associated with higher costs.
Brothers of men with prostate cancer are at a higher risk of diagnosis due to increased diagnostic activities, not genetic mutations. Incidence is highest among men with two brothers diagnosed, and detection bias contributes significantly.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
Researchers developed a method to accurately assess prostate cancer severity by analyzing magnetic resonance images and spectra. This technique has shown over 90% accuracy in distinguishing low-grade from high-grade prostate cancers, which could lead to better patient management and cost savings.
Researchers at McGill University have discovered that the facultative enzyme Mnk plays a key role in developing prostate cancer. By blocking Mnk's activity, mice became resistant to prostate cancer growth, offering hope for targeted treatments.
A pilot study published in the Journal of Endourology suggests that CO2 laser technology used with robotic prostate cancer surgery may preserve sensitive nerve areas necessary for erections and urinary continence. The technology, known as BeamPath, was found to be easy to manipulate and accurate.
A new study led by researchers at UCSF found that surgery is more effective than radiation and hormone therapies for men with high-risk prostate cancer. The study analyzed data from 7,538 men with localized disease and found a significant difference in survival rates between surgical removal of the prostate and other treatment options.
A Purdue University-led team has found a molecular compound that appears to be useful in identifying cancerous and precancerous tissue in the prostate. The compound, cholesterol sulfate, is absent in healthy prostate tissue but present in prostate cancer tumors, making it a potential marker for the disease.
Researchers identified basal cells from benign prostate tissue as a new cell-of-origin for human prostate cancer. This discovery could lead to better predictive and diagnostic tools, as well as the development of targeted treatments. The study provides a novel model system for understanding prostate cancer development and progression.
Researchers found that prostate basal cells can spawn tumors in the prostate gland, providing a new originator of prostate cancer. The study used human prostate tissue samples to develop new techniques and identified unique cell surface markers to distinguish luminal cells from basal cells.
A study found that men with low-risk prostate cancer often receive aggressive treatment, including surgery or radiation, even if their PSA levels are low. The researchers suggest that lowering the biopsy threshold for men with PSA levels below 4 nanograms per milliliter could lead to an increase in unnecessary treatments.
UT Southwestern researchers found blocking a specific enzyme step can halt tumor growth. The study suggests this approach may provide new therapy options for patients with end-stage prostate cancer, which has limited treatment choices.
A high-fat diet is found to activate nuclear factor kappa B (NF-κB) in the prostate, leading to inflammation, oxidative stress, and proliferation. The study provides direct evidence of a link between a high-fat diet and an increased risk of benign prostatic hyperplasia, prostatitis, and prostate cancer.
Researchers found that men with high-risk prostate cancer lose significantly less bone mineral content as they age compared to healthy men. The study, published in BJUI, suggests a possible link between prostate cancer and bone health, which could lead to new prevention strategies.
Gene therapy holds promise in treating prostate cancer, but challenges remain in achieving effective treatment. Researchers call for better testing systems and innovative approaches to advance the field. Prostate cancer is a leading cause of cancer death among men in the US.
Researchers have identified a functional DNA element associated with prostate cancer risk, revealing new insights into the molecular mechanisms of the disease. The study found that variants in this region can alter the expression of critical genes, increasing disease risk.